CelLBxHealth plc (AIM:CLBX)

Market Cap	6.78M -4.1%
Revenue (ttm)	1.15M -56.1%
Net Income	-12.94M
EPS	-0.02
Shares Out	1.14B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,083,011
Open	0.5970
Previous Close	0.6000
Day's Range	0.5970 - 0.6350
52-Week Range	0.5330 - 2.8000
Beta	0.69
Analysts	Strong Buy
Price Target	3.00 (+402.51%)
Est. Earnings	Jun 1, 2027

About CelLBxHealth

CelLBxHealth plc, a medical diagnostic company, develops cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix platform, emables real-time multiomic insights from blood. It also provides Portrait+ CTC Staining kit, a ready-to-use laboratory kit with analytical sensitivity and specificity for the identification, characterization, and enumeration of epithelial and mesenchymal circulating tumour cells; and CellKeep Slide, a CTC harvesting technology. In addition, the company o...

• Industry: Medical - Diagnostics & Research
• Sector: Healthcare
• Founded: 1994
• Employees: 114
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: CLBX

Financial Performance

In 2025, CelLBxHealth's revenue was 1.35 million, a decrease of -52.80% compared to the previous year's 2.86 million. Losses were -19.51 million, 37.1% more than in 2024.

Analyst Summary

According to 2 analysts, the average rating for CLBX stock is "Strong Buy." The 12-month stock price target is 3p, which is an increase of 402.51% from the latest price.

Price Target

3p

(402.51% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 6, 2026

Data Sources Report a data error